Strengthened patent protection for arfolitixorin in Japan
GOTHENBURG, Sweden, September 1, 2020 – Isofol Medical AB (publ), (Nasdaq First North Premier Growth Market: ISOFOL), has announced today that the company has further strengthened its position in the second largest market for treatment of mCRC by obtaining two new patent grants for arfolitixorin in Japan. One relates to the preparation process of the drug for injection and one relates to the dosage regimens, including those applied in the ongoing global Phase III study AGENT. Together with the already granted Active Substance Patent (API), these two patents will ensure a strong and extended